About: Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial   Goto Sponge  NotDistinct  Permalink

An Entity of Type : owl:Thing, within Data Space : data.idref.fr associated with source document(s)

AttributesValues
Author
Bibliographic Citation
  • Hogan J., Perez A., Sellier-Leclerc A. L., Vrillon I., Broux F., Nobili F., HARAMBAT Jerome, Bessenay L., Audard V., FAUDEUX C., Morin D., Pietrement C., Tellier S., Djeddi D., Eckart P., LAHOCHE A., Roussey-Kesler G., Ulinski T., Boyer O., Plaisier E., CLOAREC S., Jolivot A., Guigonis V., GUILMIN-CREPON S., Baudouin V., DOSSIER C., Deschênes G.. Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial. BMJ Open, BMJ Publishing Group, 2020, 10 (9), pp.e037306. ⟨10.1136/bmjopen-2020-037306⟩
Title
  • Efficacy and safety of intravenous immunoglobulin with rituximab versus rituximab alone in childhood-onset steroid-dependent and frequently relapsing nephrotic syndrome: protocol for a multicentre randomised controlled trial
dc:date
  • 2020
Faceted Search & Find service v1.13.91 as of Aug 16 2018


Alternative Linked Data Documents: ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software